Quadrant Capital Group LLC Vanda Pharmaceuticals Inc. Transaction History

Quadrant Capital Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$3.38 - $4.58 $145 - $196	43 Added 36.75%	160 $0
Q3 2023 Nov 14, 2023	SELL	$4.28 - $6.57 $20,860 - $32,022	-4,874 Reduced 97.66%	117 $0
Q2 2023 Aug 09, 2023	BUY	$5.9 - $6.95 $27,210 - $32,053	4,612 Added 1216.89%	4,991 $32,000
Q1 2023 May 11, 2023	SELL	$6.18 - $7.99 $828 - $1,070	-134 Reduced 26.12%	379 $2,000
Q4 2022 Feb 10, 2023	SELL	$6.87 - $10.96 $9,315 - $14,861	-1,356 Reduced 72.55%	513 $3,000
Q3 2022 Nov 10, 2022	BUY	$9.44 - $11.76 $17,492 - $21,791	1,853 Added 11581.25%	1,869 $18,000
Q4 2021 Feb 01, 2022	SELL	$15.69 - $21.14 $502 - $676	-32 Reduced 66.67%	16 $0
Q3 2021 Nov 12, 2021	BUY	$15.35 - $21.27 $122 - $170	8 Added 20.0%	48 $1,000
Q2 2021 Aug 09, 2021	BUY	$15.71 - $21.51 $377 - $516	24 Added 150.0%	40 $1,000
Q4 2020 Feb 16, 2021	BUY	$9.77 - $13.81 $156 - $220	16 New	16 $0
Q3 2020 Nov 13, 2020	SELL	$9.32 - $12.02 $419 - $540	-45 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$9.66 - $12.02 $434 - $540	45 New	45 $1,000

156

44.7M

167K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.